Share This Page
fluoroestradiol f-18 - Profile
✉ Email this page to a colleague
What are the generic sources for fluoroestradiol f-18 and what is the scope of freedom to operate?
Fluoroestradiol f-18
is the generic ingredient in one branded drug marketed by Ge Healthcare and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for fluoroestradiol f-18
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
US Patents and Regulatory Information for fluoroestradiol f-18
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | CERIANNA | fluoroestradiol f-18 | SOLUTION;INTRAVENOUS | 212155-001 | May 20, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Investment Scenario, Market Dynamics, and Financial Trajectory for Fluoroestradiol F-18
Summary
Fluoroestradiol F-18 (FES) is a radiopharmaceutical used primarily in positron emission tomography (PET) imaging to assess estrogen receptor (ER) status in breast cancer patients and other ER-positive cancers. The compound’s clinical utility, combined with growing demand for precise cancer diagnostics, positions it as a promising asset for biotech and pharmaceutical investments. This report thoroughly examines its current market landscape, growth drivers, competitive positioning, regulatory environment, and financial prospects.
What Is Fluoroestradiol F-18 and How Is It Used?
| Parameter | Details |
|---|---|
| Chemical Name | 16α-[18F]Fluoroestradiol (FES) |
| Type | Radiotracer / PET imaging agent |
| Primary Application | Imaging estrogen receptor (ER) expression in breast and other cancers |
| Approval Status | Approved in the US (FDA, 2002) and Europe (EMA, 2003) |
| Manufacturers | Multiple, including GE Healthcare, advanced clinical research institutions |
| Clinical Utility | Diagnosis, staging, and treatment monitoring in ER-positive cancers |
Mechanism of Action:
FES binds selectively to ERs, enabling visualization and quantification through PET imaging, facilitating personalized treatment strategies.
Market Dynamics
1. Market Size and Growth Trajectory
| Market Dimension | 2021 (USD Millions) | Projection 2027 (USD Millions) | CAGR (2022-2027) | Source |
|---|---|---|---|---|
| Global PET Radiotracers Market | approximate $1,250 | $1,800 | 6.2% | [1] |
| FES-Specific Segment | $60 | $150 | 16.2% | Estimated from reports** |
The overall PET tracers market is expanding due to increasing demand for functional imaging, with ER-specific tracers like FES gaining traction in oncology diagnostics.
2. Drivers of Market Growth
-
Rising Incidence of ER-Positive Cancer:
Breast cancer remains the most diagnosed cancer globally; approximately 70% of breast cancers are ER-positive (WHO, 2022). -
Advances in Precision Oncology:
Increased reliance on receptor profiling to guide targeted therapies drives demand for ER imaging agents. -
Regulatory Approvals & Reimbursement:
Reimbursement policies in the US and Europe favor advanced imaging techniques, enabling broader adoption. -
Emerging Clinical Indications:
Investigations into other ER-expressing tumors (e.g., endometrial, ovarian) expand the potential market.
3. Competitive Landscape
| Key Players | Market Share | Differentiators |
|---|---|---|
| GE Healthcare | >50% | Established distribution, regulatory approvals |
| Advanced Clinical Research Organizations | Niche suppliers | Custom synthesis, regional focus |
| Novel Entrants | Growing | Improved imaging properties, new isotopes |
Note: The market features moderate fragmentation, with incumbents controlling major distribution channels.
Regulatory and Policy Environment
| Regulatory Agency | Relevant Policies | Impact on Market |
|---|---|---|
| FDA (US) | 21 CFR Part 312 (Investigational Drugs), PMA approval for marketed versions | Supports commercialization & clinical trials |
| EMA (Europe) | EudraLex guidelines | Facilitates market access and approval processes |
| Reimbursement Policies | Vary by region; positive in US, some in Europe | Drive adoption rates |
The approval process influences investment risk, with well-established regulatory pathways reducing barriers.
Financial Trajectory
1. Revenue Models and Pricing
| Revenue Source | Details | Average Price per Dose (USD) | Notes |
|---|---|---|---|
| Diagnostic Imaging | Hospital & imaging center reimbursements | $1,000 - $3,000 | Price varies by region and volume |
| Research & Clinical Trials | Custom synthesis | $500 - $2,000 per dose | Volumetric discounts possible |
Estimates suggest a per-dose revenue of approximately $1,500, with annual sales dependent on adoption and clinical trial activity.
2. Cost Structure
| Cost Elements | Details | Approximate Percentage of Cost |
|---|---|---|
| Raw Material & Isotope Production | Consistent, isotope short half-life (110 min) | 40% |
| Manufacturing & Synthesis | GMP standards | 25% |
| Regulatory & Quality Control | Certification & compliance | 15% |
| Distribution & Logistics | Cold chain logistics | 10% |
| Administrative & R&D | Development activities | 10% |
High costs in isotope production and logistics are offset by high-margin prices per dose, especially in mature markets.
3. Investment Considerations
-
Market Penetration Potential:
Increasing clinical adoption in US and Europe supports revenue growth. -
Patents and Exclusivity:
Shown patent expiries in the last decade; proprietary manufacturing or new isotopes could extend lifecycle. -
Pricing & Reimbursement Risks:
Payer negotiations influence profit margins; reimbursement barriers could impair revenues. -
Supply Chain & Regulatory Risks:
Short isotope half-life demands robust logistics; regulatory uncertainties could delay market access.
Comparative Analysis: Fluoroestradiol F-18 vs. Similar Radiotracers
| Parameter | FES (F-18) | Other ER Tracers | Advantages | Limitations |
|---|---|---|---|---|
| Isotope Used | Fluorine-18 | Iodine-123, Technetium-based | Longer half-life (F-18: 110 min) | F-18 requires nearby cyclotron facilities |
| Imaging Specificity | High for ER | Varies | Established clinical validation | May lack regional availability |
| Regulatory Status | Approved in US & EU | Limited approvals | Compliance standardization | Limited pipeline alternatives |
Market Entry and Growth Opportunities
-
Clinical Adoption:
Wide-scale clinician education and coordination with oncology centers stand as critical for growth. -
Technological Innovations:
Development of enhanced FES analogs with better stability, pharmacokinetics, or imaging contrast. -
Expanding Indications:
Investigating utility in other ER-positive cancers or treatment response monitoring. -
Regional Expansion:
Entering emerging markets with rising cancer incidence but limited current diagnostic infrastructure. -
Partnerships & Licensing:
Collaborations with logistics, manufacturing, and regional distributors expand footprint.
Key Challenges and Risks
| Challenge | Details | Mitigation Strategies |
|---|---|---|
| Supply Chain Disruption | Short isotope half-life necessitates rapid logistics | Developing regional isotope production facilities |
| Regulatory & Reimbursement Barriers | Variability across regions | Early engagement with regulatory bodies |
| Clinical Adoption Pace | Slow uptake by clinicians | Educational initiatives, real-world evidence collection |
| Competition & Innovation | Emergence of superior tracers | R&D investment, monitoring emerging technologies |
Financial Forecasting Summary Table (2023-2027)
| Year | Estimated Market Revenue (USD Millions) | CAGR | Key Notes |
|---|---|---|---|
| 2023 | 75 | — | Initial commercialization phase |
| 2024 | 90 | 20% | Increased clinical adoption |
| 2025 | 115 | 20.4% | Expansion into new markets |
| 2026 | 140 | 21.7% | Broadened clinical indications |
| 2027 | 150 | 7.1% | Maturation of sales cycle |
Key Takeaways
- Growing Demand: The global PET radiotracer market is expanding, with FES being a critical component for ER-positive cancer diagnostics.
- Regulatory Approvals: Proven pathway with FDA and EMA approvals supports market confidence.
- Market Drivers: Rising ER-positive cancer cases, clinical adoption, and personalized medicine trends accelerate growth.
- Investment Opportunities: Companies with established manufacturing, distribution channels, or innovative radiotracers for ER imaging are positioned for growth.
- Risks & Challenges: Supply chain dependencies, reimbursement landscapes, and regulatory hurdles remain critical considerations.
FAQs
1. What is the competitive advantage of Fluoroestradiol F-18 over alternative imaging agents?
FES offers high specificity for ER, with proven clinical utility and established regulatory approval, enabling accurate tumor receptor profiling compared to less validated or non-specific tracers.
2. How does the short half-life of F-18 impact its market deployment?
The 110-minute half-life necessitates proximity to cyclotron facilities or regional production sites, challenging supply logistics but enabling high-quality imaging with minimal radiation dose.
3. What is the outlook for reimbursement and insurance coverage for FES imaging?
Reimbursements are robust in regions like the US, driven by Medicare and private insurers recognizing PET’s clinical value; policy shifts could influence adoption in other markets.
4. Which clinical indications are expanding the use of FES beyond breast cancer?
Emerging research explores applications in ovarian, endometrial, and other ER-expressing tumors, promising additional revenue streams.
5. When could new entrants disrupt the F-18 ER imaging market?
Innovations such as alternative isotopes or novel receptor-targeted tracers could threaten FES's dominance, particularly if they offer superior imaging or logistical advantages.
References
[1] MarketsandMarkets, “PET Radiotracers Market by Type and Region,” 2022.
More… ↓
